undet
scarciti
clinic
data
sever
acut
respiratori
syndrom
sar
sever
biotechnolog
diagnost
firm
join
global
rush
combat
infecti
diseas
hefti
govern
back
focu
gener
shortterm
revenu
galvan
compani
switch
focu
sar
despit
establish
market
sarsrel
product
sar
present
opportunist
scenario
similar
earli
day
aid
epidem
mani
biotech
compani
rush
refocu
effort
toward
combat
hiv
say
michael
hildreth
biotechnolog
director
ernst
young
america
palo
alto
ca
usa
geopolit
uncertainti
like
recent
war
iraq
drive
investor
favor
compani
gener
profit
quickli
say
hildreth
although
sar
market
data
scant
expert
say
diseas
deliv
profit
short
term
due
immedi
need
treatment
sar
viru
may
also
reemerg
annual
flu
season
fall
predict
scientist
increas
prospect
profit
market
first
compani
jump
antisar
bandwagon
alreadi
develop
similar
technolog
indic
exampl
roch
diagnost
basel
switzerland
collabor
genom
institut
singapor
codevelop
pcrbase
sar
detect
kit
end
juli
knowledg
instrument
technolog
money
duti
creat
test
said
baschi
duerr
spokesman
roch
diagnost
firm
hemispherx
philadelphia
pa
usa
look
therapeut
opportun
compani
immunotherapeut
drug
ampligen
recent
found
high
antivir
activ
sar
viru
vaccin
compani
genvec
gaithersburg
md
usa
look
insert
synthet
genet
partial
sequenc
sar
coronaviru
benign
adenoviru
produc
new
technolog
alreadi
use
develop
hiv
vaccin
mayb
market
mayb
revenu
earli
predict
exactli
market
size
say
duerr
aaron
davidson
vice
presid
privat
canadian
ventur
capit
firm
ventur
west
toronto
canada
believ
sar
market
may
vaccin
diagnost
investor
deem
vaccin
gener
riski
wherea
major
player
diagnost
like
roch
abbott
laboratori
abbott
park
il
usa
like
best
posit
accru
major
profit
sar
diagnost
test
avail
govern
fund
also
attract
compani
sar
chines
govern
spend
million
year
combat
sar
say
analyst
new
zealand
recent
offer
million
hardhit
china
antisar
effort
boost
intern
collabor
sar
research
similarli
health
canada
alloc
research
sar
sever
compani
like
biota
hold
victoria
australia
work
us
author
investig
possibl
way
particip
governmentfund
research
program
combat
sar
biotech
compani
also
forg
collabor
wellfund
academ
laboratori
tyson
bioresearch
hsinchu
taiwan
nation
taiwan
univers
colleg
medicin
taipei
taiwan
exampl
jointli
develop
sar
diagnost
test
identifi
patient
affect
diseas
day
onset
symptom
compani
plan
cash
potenti
licens
revenu
trend
reflect
flurri
sarsrel
patent
applic
recent
month
exampl
combimatrix
mukilteo
wa
usa
file
patent
applic
antisens
drug
sar
plexu
vaccin
san
diego
ca
usa
may
infecti
diseas
firm
siga
technolog
new
york
ny
usa
patent
denmark
cover
new
method
analyz
sar
genet
variant
eventu
carter
predict
small
number
compani
commit
resourc
develop
new
product
clinic
trial
may
year
away
sar
outbreak
arous
investor
interest
emerg
infecti
diseas
whole
say
davidson
specif
predict
antivir
like
attract
invest
futur
